<p>美敦力（NYSE:MDT - 获取免费报告）在周四发布的研究报告中，Stifel Nicolaus 将其目标股价从 90.00 美元上调至 105.00 美元，Benzinga 报道。该券商目前对这家医疗技术公司的股票维持 “持有” 评级。Stifel Nicolaus 的目标股价暗示该公司股价有 8.45% 的上涨潜力。</p>
<ul>
<li>MarketBeat 周回顾 – 08/18 - 08/22</li>
</ul>
<p>MDT 还成为其他多份报告的主题。高盛集团在 10 月 1 日的研究报告中将美敦力的目标股价从 82.00 美元下调至 81.00 美元，并对该股票设定了 “卖出” 评级。Wolfe Research 在 6 月 30 日的研究报告中将美敦力的评级从 “表现不佳” 上调至 “同业表现”。大和资本市场在 9 月 12 日的研究报告中将美敦力的目标股价从 101.00 美元上调至 104.00 美元，并给予该股票 “买入” 评级。瑞银集团在 8 月 20 日的研究报告中将美敦力的目标股价从 94.00 美元上调至 95.00 美元，并给予该股票 “中性” 评级。最后，Argus 在 8 月 26 日的研究报告中将美敦力的目标股价从 105.00 美元上调至 115.00 美元，并给予该股票 “买入” 评级。一位投资分析师对该股票给予了强烈买入评级，十二位给予了买入评级，九位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，美敦力的平均评级为 “适度买入”，平均目标股价为 101.82 美元。</p>
<p><strong>查看我们关于 MDT 的最新研究报告</strong></p>
<h2>美敦力股票下跌 1.1%</h2>
<ul>
<li>美敦力：收入投资者的机会变得更好</li>
</ul>
<p>周四午盘交易中，MDT 股票下跌 1.05 美元，报 96.82 美元。该股票交易量为 1,415,479 股，而其平均交易量为 7,597,098 股。美敦力的 1 年最低价为 79.29 美元，1 年最高价为 99.37 美元。该公司的 50 日移动平均线为 93.31 美元，200 日移动平均线为 88.65 美元。该公司的流动比率为 2.01，速动比率为 1.50，债务与股本比率为 0.54。该公司的市值为 1241.9 亿美元，市盈率为 26.68，市盈增长比率为 2.59，贝塔系数为 0.78。</p>
<p>美敦力（NYSE:MDT - 获取免费报告）最近一次发布财报是在 8 月 19 日。该医疗技术公司报告本季度每股收益为 1.26 美元，超出分析师一致预期的 1.23 美元，超出幅度为 0.03 美元。美敦力的股本回报率为 14.61%，净利润率为 13.63%。该公司本季度的收入为 85.8 亿美元，而一致预期为 83.7 亿美元。去年同期，该公司的每股收益为 1.23 美元。该公司本季度的收入同比增长 7.7%。美敦力已将其 2026 财年的指引设定为每股收益 5.600-5.660 美元。分析师平均预测美敦力本年度每股收益为 5.46 美元。</p>
<h2>美敦力的内部买卖情况</h2>
<ul>
<li>未来自动化的 5 只机器人股票推荐</li>
</ul>
<p>在其他新闻中，执行副总裁 Harry Skip Kiil 于 9 月 3 日星期三出售了 8,605 股该股票，交易均价为 91.58 美元，总交易额为 788,045.90 美元。交易后，该执行副总裁直接持有该公司 35,615 股股票，价值 3,261,621.70 美元。这代表其持股减少了 19.46%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，董事 William R. Jellison 于 8 月 25 日星期一购买了 2,500 股该股票，购买均价为 92.37 美元，总交易额为 230,925.00 美元。交易完成后，该董事直接持有该公司 5,000 股股票，价值约 461,850 美元。该交易代表其持股增加了 100.00%。该购买的披露信息可在此处找到。0.26% 的股票由公司内部人士持有。</p>
<h2>机构投资者对美敦力的看法</h2>
<p>对冲基金和其他机构投资者最近调整了对该股票的持有。1248 Management LLC 在第一季度购买了美敦力的新股份，价值 26,000 美元。Delos Wealth Advisors LLC 在第二季度购买了美敦力的新股份，价值 27,000 美元。Columbia River Financial Group LLC 在第一季度购买了美敦力的新股份，价值 28,000 美元。Twin Tree Management LP 在第一季度购买了美敦力的新股份，价值 29,000 美元。最后，Activest Wealth Management 在第一季度将其在美敦力的股份增加了 3,577.8%。Activest Wealth Management 现在持有 331 股该医疗技术公司的股票，价值 30,000 美元，此前在上个季度又购买了 322 股。目前，82.06% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>美敦力公司简介</h2>
<p>（获取免费报告）</p>
<p>美敦力公司开发、制造和销售基于设备的医疗疗法，服务于全球的医疗系统、医生、临床医生和患者。其心血管产品组合提供可植入心脏起搏器、心脏复律除颤器和心脏再同步治疗设备；心脏消融产品；可植入心脏监测系统；TYRX 产品；以及远程监测和以患者为中心的软件。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过美敦力</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>3 只高市盈率股票因未来上涨潜力而合理</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>在 AI 超级计算机交易后，Aehr Test Systems 股票是否在打折？</li>
<li>风险承受能力因人而异，不能一概而论</li>
<li>Adobe 在 iPhone 上推出 Premiere Pro，前景看好？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在美敦力吗？</h2>
<p>在考虑美敦力之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而美敦力并不在名单上。</p>
<p>虽然美敦力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美敦力

<p>Stifel Nicolaus 将美敦力（NYSE:MDT）的目标股价从 90.00 美元上调至 105.00 美元，维持 “持有” 评级。这意味着相较于前一交易日收盘价有 8.45% 的潜在上涨空间。其他分析师的观点各异，高盛将其目标下调至 81.00 美元（卖出评级），而 Argus 则将其目标上调至 115.00 美元（买入评级）。美敦力的股票最近下跌 1.1%，报 96.82 美元，市值为 1241.9 亿美元，市盈率为 26.68。该公司报告上个季度每股收益为 1.26 美元，超出预期</p>

<p>Medtronic (NYSE:MDT - Get Free Report) had its price objective lifted by stock analysts at Stifel Nicolaus from $90.00 to $105.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a &#34;hold&#34; rating on the medical technology company's stock. Stifel Nicolaus' price objective suggests a potential upside of 8.45% from the company's previous close.</p>
<div class="lb-trans"><p>美敦力（NYSE:MDT - 获取免费报告）在周四发布的研究报告中，Stifel Nicolaus 将其目标股价从 90.00 美元上调至 105.00 美元，Benzinga 报道。该券商目前对这家医疗技术公司的股票维持 “持有” 评级。Stifel Nicolaus 的目标股价暗示该公司股价有 8.45% 的上涨潜力。</p>
</div><ul>
<li>MarketBeat Week in Review – 08/18 - 08/22</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 08/18 - 08/22</li>
</ul>
</div><p>MDT has been the topic of a number of other reports. The Goldman Sachs Group dropped their price target on Medtronic from $82.00 to $81.00 and set a &#34;sell&#34; rating on the stock in a research report on Wednesday, October 1st. Wolfe Research raised Medtronic from an &#34;underperform&#34; rating to a &#34;peer perform&#34; rating in a research report on Monday, June 30th. Daiwa Capital Markets boosted their price target on Medtronic from $101.00 to $104.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, September 12th. UBS Group boosted their price target on Medtronic from $94.00 to $95.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, August 20th. Finally, Argus boosted their price target on Medtronic from $105.00 to $115.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Medtronic has an average rating of &#34;Moderate Buy&#34; and an average price target of $101.82.</p>
<div class="lb-trans"><p>MDT 还成为其他多份报告的主题。高盛集团在 10 月 1 日的研究报告中将美敦力的目标股价从 82.00 美元下调至 81.00 美元，并对该股票设定了 “卖出” 评级。Wolfe Research 在 6 月 30 日的研究报告中将美敦力的评级从 “表现不佳” 上调至 “同业表现”。大和资本市场在 9 月 12 日的研究报告中将美敦力的目标股价从 101.00 美元上调至 104.00 美元，并给予该股票 “买入” 评级。瑞银集团在 8 月 20 日的研究报告中将美敦力的目标股价从 94.00 美元上调至 95.00 美元，并给予该股票 “中性” 评级。最后，Argus 在 8 月 26 日的研究报告中将美敦力的目标股价从 105.00 美元上调至 115.00 美元，并给予该股票 “买入” 评级。一位投资分析师对该股票给予了强烈买入评级，十二位给予了买入评级，九位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，美敦力的平均评级为 “适度买入”，平均目标股价为 101.82 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on MDT</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MDT 的最新研究报告</strong></p>
</div><h2>Medtronic Stock Down 1.1%</h2>
<div class="lb-trans"><h2>美敦力股票下跌 1.1%</h2>
</div><ul>
<li>Medtronic: The Opportunity Gets Healthier for Income Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>美敦力：收入投资者的机会变得更好</li>
</ul>
</div><p>Shares of MDT stock traded down $1.05 during midday trading on Thursday, reaching $96.82. 1,415,479 shares of the stock were exchanged, compared to its average volume of 7,597,098. Medtronic has a 1 year low of $79.29 and a 1 year high of $99.37. The company's 50 day moving average is $93.31 and its two-hundred day moving average is $88.65. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The firm has a market cap of $124.19 billion, a PE ratio of 26.68, a price-to-earnings-growth ratio of 2.59 and a beta of 0.78.</p>
<div class="lb-trans"><p>周四午盘交易中，MDT 股票下跌 1.05 美元，报 96.82 美元。该股票交易量为 1,415,479 股，而其平均交易量为 7,597,098 股。美敦力的 1 年最低价为 79.29 美元，1 年最高价为 99.37 美元。该公司的 50 日移动平均线为 93.31 美元，200 日移动平均线为 88.65 美元。该公司的流动比率为 2.01，速动比率为 1.50，债务与股本比率为 0.54。该公司的市值为 1241.9 亿美元，市盈率为 26.68，市盈增长比率为 2.59，贝塔系数为 0.78。</p>
</div><p>Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter in the prior year, the business earned $1.23 EPS. The business's revenue for the quarter was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities research analysts predict that Medtronic will post 5.46 EPS for the current year.</p>
<div class="lb-trans"><p>美敦力（NYSE:MDT - 获取免费报告）最近一次发布财报是在 8 月 19 日。该医疗技术公司报告本季度每股收益为 1.26 美元，超出分析师一致预期的 1.23 美元，超出幅度为 0.03 美元。美敦力的股本回报率为 14.61%，净利润率为 13.63%。该公司本季度的收入为 85.8 亿美元，而一致预期为 83.7 亿美元。去年同期，该公司的每股收益为 1.23 美元。该公司本季度的收入同比增长 7.7%。美敦力已将其 2026 财年的指引设定为每股收益 5.600-5.660 美元。分析师平均预测美敦力本年度每股收益为 5.46 美元。</p>
</div><h2>Insider Buying and Selling at Medtronic</h2>
<div class="lb-trans"><h2>美敦力的内部买卖情况</h2>
</div><ul>
<li>5 Robotics Stocks to Buy for the Future of Automation</li>
</ul>
<div class="lb-trans"><ul>
<li>未来自动化的 5 只机器人股票推荐</li>
</ul>
</div><p>In other news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares of the company's stock, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, Director William R. Jellison purchased 2,500 shares of the stock in a transaction dated Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.26% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Harry Skip Kiil 于 9 月 3 日星期三出售了 8,605 股该股票，交易均价为 91.58 美元，总交易额为 788,045.90 美元。交易后，该执行副总裁直接持有该公司 35,615 股股票，价值 3,261,621.70 美元。这代表其持股减少了 19.46%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，董事 William R. Jellison 于 8 月 25 日星期一购买了 2,500 股该股票，购买均价为 92.37 美元，总交易额为 230,925.00 美元。交易完成后，该董事直接持有该公司 5,000 股股票，价值约 461,850 美元。该交易代表其持股增加了 100.00%。该购买的披露信息可在此处找到。0.26% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Medtronic</h2>
<div class="lb-trans"><h2>机构投资者对美敦力的看法</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. 1248 Management LLC purchased a new stake in shares of Medtronic in the 1st quarter worth $26,000. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic in the 2nd quarter worth $27,000. Columbia River Financial Group LLC purchased a new stake in shares of Medtronic in the 1st quarter worth $28,000. Twin Tree Management LP purchased a new stake in shares of Medtronic in the 1st quarter worth $29,000. Finally, Activest Wealth Management increased its stake in shares of Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company's stock worth $30,000 after purchasing an additional 322 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近调整了对该股票的持有。1248 Management LLC 在第一季度购买了美敦力的新股份，价值 26,000 美元。Delos Wealth Advisors LLC 在第二季度购买了美敦力的新股份，价值 27,000 美元。Columbia River Financial Group LLC 在第一季度购买了美敦力的新股份，价值 28,000 美元。Twin Tree Management LP 在第一季度购买了美敦力的新股份，价值 29,000 美元。最后，Activest Wealth Management 在第一季度将其在美敦力的股份增加了 3,577.8%。Activest Wealth Management 现在持有 331 股该医疗技术公司的股票，价值 30,000 美元，此前在上个季度又购买了 322 股。目前，82.06% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Medtronic Company Profile</h2>
<div class="lb-trans"><h2>美敦力公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.</p>
<div class="lb-trans"><p>美敦力公司开发、制造和销售基于设备的医疗疗法，服务于全球的医疗系统、医生、临床医生和患者。其心血管产品组合提供可植入心脏起搏器、心脏复律除颤器和心脏再同步治疗设备；心脏消融产品；可植入心脏监测系统；TYRX 产品；以及远程监测和以患者为中心的软件。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Medtronic</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>3 High P/E Stocks Justified by Future Upside Potential</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale?</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>Adobe Launches Premiere Pro on iPhone, Upside Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过美敦力</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>3 只高市盈率股票因未来上涨潜力而合理</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>在 AI 超级计算机交易后，Aehr Test Systems 股票是否在打折？</li>
<li>风险承受能力因人而异，不能一概而论</li>
<li>Adobe 在 iPhone 上推出 Premiere Pro，前景看好？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=MDT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Medtronic Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在美敦力吗？</h2>
</div><p>Before you consider Medtronic, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑美敦力之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而美敦力并不在名单上。</p>
</div><p>While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然美敦力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Stifel Nicolaus 预测美敦力（NYSE:MDT）股票将出现强劲的价格升值